Skip to main content
Premium Trial:

Request an Annual Quote

Dharmacon to Provide siRNAs to Odyssey Thera in Cell Signaling Studies

NEW YORK, Sept. 15 (GenomeWeb News) - Dharmacon and Odyssey Thera have signed a collaboration to study gene silencing in cell signaling pathways, the companies said today.

 

Under the agreement, Dharmacon, of Lafayette, Colo., will synthesize its siRNA reagents for targets that Odyssey Thera, of San Ramon, Calif., provides. These targets are associated with angiogenesis, apoptosis, inflammation, and other disease-related events, the companies said.  

 

Odyssey researchers will combine these siRNA reagents with the company's protein-fragment complementation assay, which is used to quantify and analyze signaling events in living human cells. Together, these technologies are expected to enable the researchers to analyze the way that gene silencing affects downstream events in cell signaling pathways, as well as measuring off-pathway effects.

 

Odyssey said it is planning to use the information gleaned through this collaboration in identification of novel targets, as well as potential nucleic acid and small molecule therapeutics, and high-throughput screening assays. Dharmacon said the collaboration will help it broaden its understanding of "the specificity and potency of siRNA's in the context of a cellular readout," according to a company statement.

 

The companies did not disclose the financial terms of the agreement.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.